US 12,419,877 B2
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
James Densmore Copp, Silverthorne, CO (US); Ann W. Newman, Lafayette, IN (US); and Anne Luong, Mississauga (CA)
Assigned to Akebia Therapeutics, Inc., Cambridge, MA (US)
Filed by Akebia Therapeutics, Inc., Cambridge, MA (US)
Filed on May 17, 2023, as Appl. No. 18/319,287.
Application 15/994,348 is a division of application No. 15/608,186, filed on May 30, 2017, granted, now 9,987,262, issued on Jun. 5, 2018.
Application 15/608,186 is a division of application No. 14/541,284, filed on Nov. 14, 2014, granted, now 9,701,636, issued on Jul. 11, 2017.
Application 18/319,287 is a continuation of application No. 17/347,700, filed on Jun. 15, 2021, granted, now 11,690,836.
Application 17/347,700 is a continuation of application No. 16/786,187, filed on Feb. 10, 2020, granted, now 11,065,237, issued on Jul. 20, 2021.
Application 16/786,187 is a continuation of application No. 16/178,191, filed on Nov. 1, 2018, granted, now 10,596,158, issued on Mar. 24, 2020.
Application 16/178,191 is a continuation of application No. 15/994,348, filed on May 31, 2018, granted, now 10,149,842, issued on Dec. 11, 2018.
Claims priority of provisional application 61/904,803, filed on Nov. 15, 2013.
Prior Publication US 2024/0122910 A1, Apr. 18, 2024
Int. Cl. C07D 213/65 (2006.01); A61K 9/14 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/4418 (2006.01); A61K 31/444 (2006.01); C07D 213/803 (2006.01); C07D 213/81 (2006.01); C07D 221/00 (2006.01)
CPC A61K 31/444 (2013.01) [A61K 9/14 (2013.01); A61K 9/2054 (2013.01); A61K 9/48 (2013.01); A61K 9/4866 (2013.01); A61K 31/4418 (2013.01); C07D 213/803 (2013.01); C07D 213/81 (2013.01); C07B 2200/13 (2013.01); C07D 221/00 (2013.01)] 20 Claims
 
1. A method for preparing the Crystalline Compound (I):

OG Complex Work Unit Chemistry
comprising
a) preparing a solution of a Compound (I) in an organic solvent that is acetonitrile; and
b) evaporating the organic solvent;
wherein the Crystalline Compound (1) has X-ray powder diffraction pattern comprising peaks at 8.6, 15.3, 22.7, and 28.1±0.2° 2θ.